Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years of age or older. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.~2. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: a) clinical evidence of progressive RGC dysfunction and degeneration using visual field and/or a structural modality. There must be at least 3 reliable visual fields within 14 months prior to entering into the study; b) residual visual field preservation in at least 1 quadrant.~3. Participant must be medically able to undergo the testing required in the flowsheet of exam procedures.~4. Females of childbearing potential must agree to use an effective form of birth control.~Exclusion Criteria:~1. Participant has another optic nerve or retinal degenerative disease or co-morbidity causing significant vision loss, irrespective of whether it is currently treated or untreated, that could limit the possibility of visual recovery.~2. Participant is blind in one eye.~3. Participant has a requirement of acyclovir and/or related products during study duration. 4- Participant has evidence of corneal opacification or lack of optical clarity.~4. Participant has evidence of corneal opacification or lack of optical clarity.~5. Participant has undergone lens removal in the last 3 months, with or without intra-ocular lens implantation, or has undergone intra-ocular lens replacement within 3 months, or has undergone any other ocular surgery within 9 months prior to initiation of study drug.~6. Participant is receiving systemic steroids or other immunosuppressive medications.~7. Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a non-clinically approved drug by ocular or systemic administration.~8. Participant has uveitis or other ocular inflammatory disease.~9. Participant has diabetic macular edema.~10. Participant has a history of ocular herpes zoster.~11. Participant is on chemotherapy.~12. Participant has a history of malignancy, not counting basal cell carcinomas, UNLESS it was treated successfully 2 years prior to inclusion in the trial.~13. Known hypersensitivity to one of the components of the study or procedural medications.~14. History of drug, medication or alcohol abuse or addiction.~15. Females of childbearing potential (those who are not surgically sterilized or post- menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:~    1. are currently pregnant or,~   2. have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,~   3. intend to become pregnant during the study treatment period or,~   4. are breast-feeding or,~   5. not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD during the entire course of and 30 days after the study treatment periods.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- rhNGF (Type: EXPERIMENTAL): rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
- Vehicle (Type: PLACEBO_COMPARATOR): Ophthalmic Placebo solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete